Literature DB >> 17570346

Stimuli linked to ethanol availability activate hypothalamic CART and orexin neurons in a reinstatement model of relapse.

Christopher V Dayas1, Tresa M McGranahan, Rémi Martin-Fardon, Friedbert Weiss.   

Abstract

BACKGROUND: There has been a recent upsurge of interest in the role of hypothalamic feeding peptides, in particular, orexin (hypocretin), in drug-seeking behavior. However, the potential role of other hypothalamic feeding peptides, such as cocaine- and amphetamine-regulated transcript (CART), in conditioned reinstatement has yet to be explored.
METHODS: Animals were exposed to environmental stimuli previously associated with ethanol availability (EtOH S+), and sections from the hypothalamus and paraventricular thalamus (PVT), a recipient of CART and orexin innervation, were dual labeled for Fos-protein and either CART or orexin.
RESULTS: Significantly larger numbers of Fos-positive arcuate nucleus CART and hypothalamic orexin neurons were seen in animals exposed to the EtOH S+ compared with nonreward S- animals. Presentation of the EtOH S+ also increased numbers of Fos-positive PVT neurons. Fos-positive PVT neurons were observed to be closely associated with orexin and CART terminal fields.
CONCLUSIONS: Taken together, these findings suggest that activation of hypothalamic neuropeptide systems may be a common mechanism underlying drug-seeking behavior.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17570346     DOI: 10.1016/j.biopsych.2007.02.002

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  115 in total

1.  Medial dorsal hypothalamus mediates the inhibition of reward seeking after extinction.

Authors:  Nathan J Marchant; Teri M Furlong; Gavan P McNally
Journal:  J Neurosci       Date:  2010-10-20       Impact factor: 6.167

2.  New operant model of reinstatement of food-seeking behavior in mice.

Authors:  Elena Martín-García; Aurelijus Burokas; Elzbieta Kostrzewa; Agnieszka Gieryk; Michal Korostynski; Barbara Ziolkowska; Barbara Przewlocka; Ryszard Przewlocki; Rafael Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2010-12-14       Impact factor: 4.530

Review 3.  Hypocretin/orexin involvement in reward and reinforcement.

Authors:  Rodrigo A España
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

4.  Cocaine potentiates excitatory drive in the perifornical/lateral hypothalamus.

Authors:  Jiann Wei Yeoh; Morgan H James; Phillip Jobling; Jaideep S Bains; Brett A Graham; Christopher V Dayas
Journal:  J Physiol       Date:  2012-05-28       Impact factor: 5.182

5.  Orexins in the paraventricular nucleus of the thalamus mediate anxiety-like responses in rats.

Authors:  Yonghui Li; Sa Li; Chuguang Wei; Huiying Wang; Nan Sui; Gilbert J Kirouac
Journal:  Psychopharmacology (Berl)       Date:  2010-07-20       Impact factor: 4.530

6.  The Cerebellar GABAAR System as a Potential Target for Treating Alcohol Use Disorder.

Authors:  David J Rossi; Ben D Richardson
Journal:  Handb Exp Pharmacol       Date:  2018

Review 7.  Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity.

Authors:  Angie M Cason; Rachel J Smith; Pouya Tahsili-Fahadan; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Physiol Behav       Date:  2010-03-23

8.  Differential effects of acute and chronic ethanol exposure on orexin expression in the perifornical lateral hypothalamus.

Authors:  Irene Morganstern; Guo-Q Chang; Jessica R Barson; Zhiyu Ye; Olga Karatayev; Sarah F Leibowitz
Journal:  Alcohol Clin Exp Res       Date:  2010-03-10       Impact factor: 3.455

9.  Localization of CART-positive neurons in the amygdaloid body and the relationship between their immunoreactivity and the sex steroid level.

Authors:  A V Akhmadeev
Journal:  Neurosci Behav Physiol       Date:  2010-03-26

10.  Attenuation of saccharin-seeking in rats by orexin/hypocretin receptor 1 antagonist.

Authors:  Angie M Cason; Gary Aston-Jones
Journal:  Psychopharmacology (Berl)       Date:  2013-03-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.